Curated news and analysis on clinical trials, drug approvals, and medical research.
Phase 2 data for BW-20805 showed up to 100% reduction in HAE attacks with dosing intervals up to 6 months, while onvuzosiran (ADX-324) advances to Phase 3 trials with semi-annual dosing targeting prekallikrein.
BriaCell Therapeutics announced an asset purchase agreement transferring its Soluble CD80 license to majority-owned subsidiary BriaPro, while four abstracts were accepted for presentation at the 2026 AACR Annual Meeting.
State investigators have begun searching Jeffrey Epstein's former New Mexico ranch, while legislators launch a separate investigation into past activities at the property and potential official corruption.
Recent publications and collaborations advance glioblastoma research through blood-based microRNA diagnostics, combination immunotherapy trials, and identification of MOV10 as a prognostic biomarker and therapeutic target.
Eight drug development inputs and services companies reported mixed Q4 earnings, with revenues beating consensus estimates by 1.5% as a group. Charles River Laboratories, Medpace, Fortrea, and Repligen showed varied performance.
The global 3D bioprinted human tissue market is projected to grow from $2.5 billion in 2025 to $3.9 billion by 2035 at a 4.6% CAGR, driven by regenerative medicine demand and advances in hybrid hydrogel materials for tissue engineering.
Opus Genetics reported positive early data from its BEST1 gene therapy program and expects FDA action on its presbyopia treatment in October 2026. Ultragenyx announced 2025 revenue of $673 million and initiated a strategic restructuring plan targeting profitability in 2027.
AstraZeneca won a Federal Court injunction blocking Pharmacor from selling generic dapagliflozin products in Australia until a full patent trial. The patent expires October 22, 2027.
Pharmaceutical companies are developing innovative hair loss treatments that directly activate hair growth pathways rather than suppressing male hormones, with several candidates entering clinical trials and promising enhanced safety profiles.
Shanghai Henlius Biotech received approval from China's National Medical Products Administration to begin a phase 1 clinical trial of HLX316, a B7-H3-targeting sialidase Fc fusion protein for advanced or metastatic solid tumors.
Researchers unveil tumor-intrinsic role of PD-L1 in lung cancer progression and develop systematic method for discovering molecular glues that selectively degrade disease proteins, while advances in immunology research aim to improve care for immune-mediated inflammatory diseases.
Natco Pharma has received CDSCO approval to manufacture and market generic semaglutide injection in India, with a planned March 2026 launch. Eris Lifesciences will commercialize the product through a partnership.
New research from the University of Missouri-Columbia reveals that targeted cancer therapies, including tyrosine kinase inhibitors, antibody-drug conjugates, and CAR-T cell therapies, cause distinct patterns of gastrointestinal injury that are often underrecognized.
Allergic rhinitis demonstrates both protective and risk associations with COVID-19 symptoms, while sublingual immunotherapy modifies respiratory and fever outcomes in patients with the condition.
Total spending on direct-to-consumer prescription drug advertising reached $9 billion in 2024, prompting renewed debate over whether such marketing should be legal. The U.S. and New Zealand remain the only developed nations allowing the practice.
Roche's experimental breast cancer pill giredestrant combined with a CDK4/6 inhibitor failed to meet its primary endpoint in a Phase III trial for first-line treatment of ER-positive, HER2-negative advanced breast cancer, marking a setback for the drugmaker's next-generation hormone therapy program.
The FDA approved navepegritide, a once-weekly injectable therapy for achondroplasia, while phase 3 data showed infigratinib, an investigational oral medication, achieved the highest growth velocity reported in randomized trials for the condition.
Acurx Pharmaceuticals announced a new clinical trial program for ibezapolstat in patients with recurrent C. difficile infection, building on Phase 2 results showing 96% clinical cure rates with no recurrence while sparing the gut microbiome.
GE HealthCare announced FDA 510(k) clearances for its View diagnostic viewer within the Genesis Radiology Workspace and three new Signa MRI systems, including helium-free technology and AI-powered workflow solutions.
The FDA has accepted Roche's new drug application for giredestrant plus everolimus to treat ER-positive, HER2-negative, ESR1-mutated advanced breast cancer following prior endocrine therapy, with a decision expected by December 18, 2026.
